Viral Vector Manufacturing Market - Forecast(2024 - 2030)

Report Code: HCR 89466 Report Format: PDF + Excel

Viral Vector Manufacturing Market Overview:

The Viral Vector Manufacturing Market size is estimated to reach US $2522 Million by 2030, growing at a CAGR of 20.1% during the forecast period 2023-2030. The viral vector manufacturing market is an emerging field that involves the production of viral vectors, which are used as vehicles to deliver genes into cells for gene therapy or vaccine development. Viral vectors are modified viruses that are used to transport genetic material into a patient's cells to correct or replace defective genes or to induce an immune response against a specific disease.


The market for viral vector manufacturing is rapidly expanding due to the increasing number of gene therapy clinical trials and the growing demand for gene therapy treatments. Gene therapy is a promising area of medicine, and there is a growing interest in developing new gene therapies for various diseases, including cancer, rare genetic disorders, and infectious diseases.

The viral vector manufacturing market is expected to grow significantly in the coming years, driven by the increasing demand for gene therapies, advancements in viral vector technology, and increasing investments in research and development.

The market is highly competitive, with several key players operating in the industry, including Thermo Fisher Scientific, Lonza Group, Fujifilm Diosynth Biotechnologies, Merck KGaA, and Oxford Biomedica. These companies are investing heavily in research and development to develop new viral vector manufacturing technologies and expand their production capacities to meet the growing demand for gene therapy treatments.

Market Snapshot:

Viral Vector Manufacturing Market - Report Coverage:

The "Viral Vector Manufacturing Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Biochar Market.


AttributeSegment


By Type

  • Retroviral Vectors 

  • Adeno-associated Viral Vectors

  • Lentiviral Vectors

  • Adeno-associated Vectors

  • Others


By Disease Estimates

  • Cancer

  • Genetic Disorders

  • Infectious Diseases

  • cardiovascular Diseases

  • Diabetes

  •  Others

 



By Application

  • Gene Therapy

  • Vaccinology Development

  • Biopharmaceutical & Pharmaceutical Discover

  • Biomedical Research

  • Protein production

  • Others


By Distribution Channel

  • Direct Sales

  • Distributors

  • Online Sales

  • Others



By Geography

  • North America (U.S., Canada and Mexico)

  • Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe),

  • Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific),

  • South America (Brazil, Argentina, Chile, Colombia and the Rest of South America)

  • Rest of the World (Middle East and Africa).


Viral Vector Manufacturing Market - Top Trends


Increasing demand for AAV vectors: Adeno-associated virus (AAV) vectors are currently the most widely used viral vectors in gene therapy due to their safety profile and ability to deliver genetic material to specific target cells. As a result, there is increasing demand for AAV vector manufacturing, and companies are investing heavily in expanding their AAV vector manufacturing capabilities.

Development of new viral vector technologies: In addition to AAV vectors, there is increasing interest in developing new viral vector technologies, such as lentivirus and adenovirus vectors, to overcome the limitations of current viral vectors. Companies are investing in developing these new vector technologies and improving their manufacturing processes.

Increasing automation in viral vector manufacturing: As the demand for viral vectors continues to grow, there is increasing pressure on companies to improve their manufacturing efficiency and reduce costs. To address this, companies are investing in automation technologies for viral vector manufacturing, which can improve manufacturing speed, consistency, and scalability.

Expansion of manufacturing facilities: To meet the increasing demand for viral vectors, companies are expanding their manufacturing facilities and building new facilities around the world. This includes building larger-scale facilities capable of producing viral vectors at commercial scale, as well as establishing facilities in new regions to improve access to viral vectors globally.

Growing use of gene therapy in rare diseases: Gene therapy has shown promise in treating rare diseases, and there is increasing interest in developing gene therapies for these conditions. This has led to increased demand for viral vectors for gene therapy, and companies are investing in developing gene therapies for rare diseases and expanding their manufacturing capabilities to meet this demand. 

The Viral Vector Manufacturing Market - Company Analysis

 

The viral vector manufacturing market is a complex and rapidly evolving industry that has seen significant growth in recent years. Many companies are competing for market share, but only a select few have established themselves as leaders in this space.

One such company is Lonza Group AG, which has a strong presence in the viral vector contract manufacturing market. The company's expertise in cell and gene therapy has helped it to establish itself as a leader in the field, and it has long-standing partnerships with many of the top pharmaceutical and biotech companies in the world.

Another key player in this space is Thermo Fisher Scientific Inc., which provides a range of services and products for viral vector production. The company has a unique advantage because it can provide end-to-end solutions for its clients, including the production of viral vectors, purification, and quality control.

Other companies that are making a name for themselves in this market include Cobra Biologics, FUJIFILM Diosynth Biotechnologies, and Oxford BioMedica. All of these companies have unique capabilities and areas of expertise, which allows them to compete in the viral vector manufacturing space.

In conclusion, the viral vector manufacturing market is a complex and ever-changing industry that requires companies to have expertise in a range of areas. Lonza Group AG, Thermo Fisher Scientific Inc., Cobra Biologics, FUJIFILM Diosynth Biotechnologies, and Oxford BioMedica are just a few of the companies that are leading the way in this exciting field.

Key Market Players:


Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies players in the Viral Vector Manufacturing Market adopt. The top 10 companies in Viral Vector Manufacturing Market are listed below:

  1. Addgene, Inc.
  2. Advanced BioScience Laboratories, Inc. (ABL, Inc.)
  3. Aldevron, L.L.C.
  4. AstraZeneca
  5. Audentes Therapeutics
  6. Batavia Biosciences B.V
  7. BioMarin Pharmaceutical
  8. BioNTech IMFS GmbH
  9. Biovion oy
  10. Catalent Inc
  11. CEVEC Pharmaceuticals GmbH
  12. CGT Catapult
  13. Danaher (Cytiva)
  14. General Electric Company (GE Healthcare)
  15. Genezen
  16. Johnson & Johnson (Janssen Global Services LLC)
  17. Sanofi
  18. Takara Bio.
  19. Thermo Fisher Scientific
  20. Vibalogics

Scope of the Report:


Report MetricDetails

Base Year Considered

2022

Forecast Period

2023–2030

CAGR

18.9%

Market Size in 2030

US $2522 Million

Segments Covered

Vector Type, Disease, Application, Distribution Channel and Region


Geographies Covered

  • North America (U.S., Canada and Mexico),
  • Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe),
  • Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific),
  • South America (Brazil, Argentina, Chile, Colombia and Rest of South America),
  • Rest of the World (Middle East and Africa).





Key Market Players

  1. Addgene, Inc.
  2. Advanced BioScience Laboratories, Inc. (ABL, Inc.)
  3. Aldevron, L.L.C.
  4.  AstraZeneca
  5. Audentes Therapeutics
  6. CGT Catapult
  7. Danaher (Cytiva)
  8. Johnson & Johnson (Janssen Global Services LLC)
  9. Sanofi
  10. Vibalogics


For more Lifesciences and Healthcare Market reports, please click here

1.Viral Vector Manufacturing Market Overview
    1.1.Definitions and Scope
2.Viral Vector Manufacturing Market– Executive Summary
3.Viral Vector Manufacturing Market– Market Landscape
    3.1 company Benchmarking – Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis – Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4.Viral Vector Manufacturing Market– Startup Company Scenario
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5.Viral Vector Manufacturing Market– Market Entry Scenario Premium
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6.Viral Vector Manufacturing Market– Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porter’s Five Force Model
        6.3.1 Bargaining Power of Suppliers
        6.3.2 Bargaining Powers of Customers
        6.3.3 Threat of New Entrants
        6.3.4 Rivalry Among Existing Players
        6.3.5 Threat of Substitutes
7.Viral Vector Manufacturing Market– Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8.Viral Vector Manufacturing Market– By Type (Market Size - $Million/$Billion)
    8.1 Retroviral Vectors
        8.1.1 Market Trends by Region 
        8.1.2 Market Share & Forecast by Region
    8.2 Adenoviral Vectors
        8.2.1 Market Trends by Region
        8.2.2 Market Share & Forecast by Region
    8.3 Adeno-associated Viral Vectors
       8.3.1 Market Trends by Region
       8.3.2 Market Share & Forecast by Region
    8.4 Lentiviral Vectors
        8.4.1 Market Trends by Region
        8.4.2 Market Share & Forecast by Region
    8.5 Others (Herpes Simplex Virus Vectors, Vaccinia Virus Vectors, etc.)
9.Viral Vector Manufacturing Market–by Disease Estimates & Trend Analysis (Market Size - $Million/$Billion)
    9.1 Cancer
        9.1.1 Market Share & Forecast by Region
        9.1.2 Market Share & Forecast by Region
    9.2 Genetic Disorders
        9.2.1 Market Trends by Region
        9.2.2 Market Share & Forecast by Region
    9.3Infectious Disorders
        9.3.1 Market Trends by Region
        9.3.2 Market Share & Forecast by Region
    9.4Others (cardiovascular Diseases, Diabetes, etc.)
10.Viral Vector Manufacturing Market– by Application (Market Size - $Million/$Billion)
    10.1 Gene Therapy
        10.1.1 Market Trends by Region
        10.1.2 Market Share & Forecast by Region
    10.2 Vaccinology Development
        10.2.1 Market Trends by Region
        10.2.2 Market Share & Forecast by Region
    10.3 Biopharmaceutical & Pharmaceutical Discover
        10.3.1 Market Trends by Region
        10.3.2 Market Share & Forecast by Region
    10.4 Biomedical Research
        10.4.1 Market Trends by Region
        10.4.2 Market Share & Forecast by Region
    10.5 Protein production
        10.5.1 Market Trends by Region
        10.5.2 Market Share & Forecast by Region
    10.6 Others (Drug Delivery, Cell Therapy, etc.)
11.Viral Vector Manufacturing Market– by Distribution Channel (Market Size - $Million/$Billion)
    11.1 Introduction
    11.2 Direct Sales 
        11.2 1Market Trends by Region
        11.2 2Market Share & Forecast by Region
    11.3 Distributors
        11.3.1 Market Trends by Region
        11.3.2 Market Share & Forecast by Region
    11.4 Online Sales
        11.4.1 Market Trends by Region
        11.4.2 Market Share & Forecast by Region
12.Viral Vector Manufacturing Market– by Geography (Market Size - $Million/$Billion)
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 Germany
        12.2.2 France
        12.2.3 U.K.
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Japan
        12.3.3 South Korea
        12.3.4 India
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13.Viral Vector Manufacturing Market– Market Entropy
    13.1 New product launches
    13.2 M&A’s, collaborations, JVs and partnerships
14 Viral Vector Manufacturing Market– Industry Competition Landscape
    14.1 Market Share Analysis
        14.1.1 Market Share by Technology – Key Companies
        14.1.2 Market Share by Country – Key Companies
        14.1.3 Market Share by Region – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15.Viral Vector Manufacturing Market– Key Company List by Country Premium
16.Viral Vector Manufacturing Market– Company Analysis
    16.1 Addgene, Inc.
    16.2 Advanced BioScience Laboratories, Inc. (ABL, Inc.)
    16.3 Aldevron, L.L.C.
    16.4 AstraZeneca
    16.5 Audentes Therapeutics
    16.6 Batavia Biosciences B.V
    16.7 BioMarin Pharmaceutical
    16.8 BioNTech IMFS GmbH
    16.9 Biovion oy
    16.10 Catalent Inc
    16.11 CEVEC Pharmaceuticals GmbH
    16.12 CGT Catapult
    16.13 Danaher (Cytiva)
    16.14 General Electric Company (GE Healthcare)
    16.15 Genezen
    16.16 Johnson & Johnson (Janssen Global Services LLC)
    16.17 Sanofi
    16.18 Takara Bio.
    16.19 Thermo Fisher Scientific
    16.20 Vibalogics

* "Financials would be provided to private companies on best-efforts basis." 
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.

LIST OF TABLES

1.Global Viral Vector Manufacturing Market, By Type Market 2023-2030 ($M)
1.1 Retroviral Vector Market 2023-2030 ($M) - Global Industry Research
1.1.1 Lentiviral Vector Market 2023-2030 ($M)
1.1.2 Gamma-Retroviral Vector Market 2023-2030 ($M)
1.2 Adenoviral Vector Market 2023-2030 ($M) - Global Industry Research
1.3 Adeno-Associated Viral Vector Market 2023-2030 ($M) - Global Industry Research
2.Global Viral Vector Manufacturing Market, By Disease Market 2023-2030 ($M)
2.1 Cancer Market 2023-2030 ($M) - Global Industry Research
2.2 Genetic Disorder Market 2023-2030 ($M) - Global Industry Research
2.3 Infectious Disease Market 2023-2030 ($M) - Global Industry Research
3.Global Viral Vector Manufacturing Market, By End User Market 2023-2030 ($M)
3.1 Pharmaceutical And Biopharmaceutical Company Market 2023-2030 ($M) - Global Industry Research
3.2 Research Institute Market 2023-2030 ($M) - Global Industry Research
4.Global Viral Vector Manufacturing Market, By Type Market 2023-2030 (Volume/Units)
4.1 Retroviral Vector Market 2023-2030 (Volume/Units) - Global Industry Research
4.1.1 Lentiviral Vector Market 2023-2030 (Volume/Units)
4.1.2 Gamma-Retroviral Vector Market 2023-2030 (Volume/Units)
4.2 Adenoviral Vector Market 2023-2030 (Volume/Units) - Global Industry Research
4.3 Adeno-Associated Viral Vector Market 2023-2030 (Volume/Units) - Global Industry Research
5.Global Viral Vector Manufacturing Market, By Disease Market 2023-2030 (Volume/Units)
5.1 Cancer Market 2023-2030 (Volume/Units) - Global Industry Research
5.2 Genetic Disorder Market 2023-2030 (Volume/Units) - Global Industry Research
5.3 Infectious Disease Market 2023-2030 (Volume/Units) - Global Industry Research
6.Global Viral Vector Manufacturing Market, By End User Market 2023-2030 (Volume/Units)
6.1 Pharmaceutical And Biopharmaceutical Company Market 2023-2030 (Volume/Units) - Global Industry Research
6.2 Research Institute Market 2023-2030 (Volume/Units) - Global Industry Research
7.North America Viral Vector Manufacturing Market, By Type Market 2023-2030 ($M)
7.1 Retroviral Vector Market 2023-2030 ($M) - Regional Industry Research
7.1.1 Lentiviral Vector Market 2023-2030 ($M)
7.1.2 Gamma-Retroviral Vector Market 2023-2030 ($M)
7.2 Adenoviral Vector Market 2023-2030 ($M) - Regional Industry Research
7.3 Adeno-Associated Viral Vector Market 2023-2030 ($M) - Regional Industry Research
8.North America Viral Vector Manufacturing Market, By Disease Market 2023-2030 ($M)
8.1 Cancer Market 2023-2030 ($M) - Regional Industry Research
8.2 Genetic Disorder Market 2023-2030 ($M) - Regional Industry Research
8.3 Infectious Disease Market 2023-2030 ($M) - Regional Industry Research
9.North America Viral Vector Manufacturing Market, By End User Market 2023-2030 ($M)
9.1 Pharmaceutical And Biopharmaceutical Company Market 2023-2030 ($M) - Regional Industry Research
9.2 Research Institute Market 2023-2030 ($M) - Regional Industry Research
10.South America Viral Vector Manufacturing Market, By Type Market 2023-2030 ($M)
10.1 Retroviral Vector Market 2023-2030 ($M) - Regional Industry Research
10.1.1 Lentiviral Vector Market 2023-2030 ($M)
10.1.2 Gamma-Retroviral Vector Market 2023-2030 ($M)
10.2 Adenoviral Vector Market 2023-2030 ($M) - Regional Industry Research
10.3 Adeno-Associated Viral Vector Market 2023-2030 ($M) - Regional Industry Research
11.South America Viral Vector Manufacturing Market, By Disease Market 2023-2030 ($M)
11.1 Cancer Market 2023-2030 ($M) - Regional Industry Research
11.2 Genetic Disorder Market 2023-2030 ($M) - Regional Industry Research
11.3 Infectious Disease Market 2023-2030 ($M) - Regional Industry Research
12.South America Viral Vector Manufacturing Market, By End User Market 2023-2030 ($M)
12.1 Pharmaceutical And Biopharmaceutical Company Market 2023-2030 ($M) - Regional Industry Research
12.2 Research Institute Market 2023-2030 ($M) - Regional Industry Research
13.Europe Viral Vector Manufacturing Market, By Type Market 2023-2030 ($M)
13.1 Retroviral Vector Market 2023-2030 ($M) - Regional Industry Research
13.1.1 Lentiviral Vector Market 2023-2030 ($M)
13.1.2 Gamma-Retroviral Vector Market 2023-2030 ($M)
13.2 Adenoviral Vector Market 2023-2030 ($M) - Regional Industry Research
13.3 Adeno-Associated Viral Vector Market 2023-2030 ($M) - Regional Industry Research
14.Europe Viral Vector Manufacturing Market, By Disease Market 2023-2030 ($M)
14.1 Cancer Market 2023-2030 ($M) - Regional Industry Research
14.2 Genetic Disorder Market 2023-2030 ($M) - Regional Industry Research
14.3 Infectious Disease Market 2023-2030 ($M) - Regional Industry Research
15.Europe Viral Vector Manufacturing Market, By End User Market 2023-2030 ($M)
15.1 Pharmaceutical And Biopharmaceutical Company Market 2023-2030 ($M) - Regional Industry Research
15.2 Research Institute Market 2023-2030 ($M) - Regional Industry Research
16.APAC Viral Vector Manufacturing Market, By Type Market 2023-2030 ($M)
16.1 Retroviral Vector Market 2023-2030 ($M) - Regional Industry Research
16.1.1 Lentiviral Vector Market 2023-2030 ($M)
16.1.2 Gamma-Retroviral Vector Market 2023-2030 ($M)
16.2 Adenoviral Vector Market 2023-2030 ($M) - Regional Industry Research
16.3 Adeno-Associated Viral Vector Market 2023-2030 ($M) - Regional Industry Research
17.APAC Viral Vector Manufacturing Market, By Disease Market 2023-2030 ($M)
17.1 Cancer Market 2023-2030 ($M) - Regional Industry Research
17.2 Genetic Disorder Market 2023-2030 ($M) - Regional Industry Research
17.3 Infectious Disease Market 2023-2030 ($M) - Regional Industry Research
18.APAC Viral Vector Manufacturing Market, By End User Market 2023-2030 ($M)
18.1 Pharmaceutical And Biopharmaceutical Company Market 2023-2030 ($M) - Regional Industry Research
18.2 Research Institute Market 2023-2030 ($M) - Regional Industry Research
19.MENA Viral Vector Manufacturing Market, By Type Market 2023-2030 ($M)
19.1 Retroviral Vector Market 2023-2030 ($M) - Regional Industry Research
19.1.1 Lentiviral Vector Market 2023-2030 ($M)
19.1.2 Gamma-Retroviral Vector Market 2023-2030 ($M)
19.2 Adenoviral Vector Market 2023-2030 ($M) - Regional Industry Research
19.3 Adeno-Associated Viral Vector Market 2023-2030 ($M) - Regional Industry Research
20.MENA Viral Vector Manufacturing Market, By Disease Market 2023-2030 ($M)
20.1 Cancer Market 2023-2030 ($M) - Regional Industry Research
20.2 Genetic Disorder Market 2023-2030 ($M) - Regional Industry Research
20.3 Infectious Disease Market 2023-2030 ($M) - Regional Industry Research
21.MENA Viral Vector Manufacturing Market, By End User Market 2023-2030 ($M)
21.1 Pharmaceutical And Biopharmaceutical Company Market 2023-2030 ($M) - Regional Industry Research
21.2 Research Institute Market 2023-2030 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
2.Canada Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
3.Mexico Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
4.Brazil Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
5.Argentina Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
6.Peru Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
7.Colombia Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
8.Chile Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
9.Rest of South America Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
10.UK Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
11.Germany Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
12.France Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
13.Italy Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
14.Spain Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
15.Rest of Europe Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
16.China Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
17.India Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
18.Japan Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
19.South Korea Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
20.South Africa Viral Vector Manufacturing Market Revenue, 2023-2030 ($M)
21.North America Viral Vector Manufacturing By Application
22.South America Viral Vector Manufacturing By Application
23.Europe Viral Vector Manufacturing By Application
24.APAC Viral Vector Manufacturing By Application
25.MENA Viral Vector Manufacturing By Application
26.Lonza, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Merck Kgaa, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Oxford Biomedica, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Cobra Biologics, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Novasep, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Spark Therapeutic, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Kaneka Eurogentec, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Finvector Vision Therapy, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Brammer Bio, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Cell And Gene Therapy Catapult, Sales /Revenue, 2015-2018 ($Mn/$Bn)
36.Fujifilm Holding Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
37.Uniqure, Sales /Revenue, 2015-2018 ($Mn/$Bn)
38.Regenxbio, Sales /Revenue, 2015-2018 ($Mn/$Bn)
39.Massbiologics, Sales /Revenue, 2015-2018 ($Mn/$Bn)

The Viral Vector Manufacturing Market is forecast to grow at 18.9% during the forecast period 2023-2030.

The Global Viral Vector Manufacturing Market size is estimated to be US$ 634 Million in 2022 and is projected to reach US $2522 Million by 2030.

The leading players in the Viral Vector Manufacturing Market are Addgene, Inc., Advanced BioScience Laboratories, Inc. (ABL, Inc.), Aldevron, L.L.C., AstraZeneca, Sanofi and others.